BioMarin Pharmaceutical (NASDAQ:BMRN) had its price target lowered by analysts at Piper Sandler from $122.00 to $84.00. They now have an "overweight" rating on the stock.
Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments [Yahoo! Finance]
Should You Buy BioMarin Pharmaceutical Before Feb. 18? [Yahoo! Finance]
BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility
BioMarin's Amicus Deal Funding Reshapes Debt Load And Rare Disease Reach [Yahoo! Finance]